Celldex Therapeutics CFO plans March 2027 retirement
Celldex Therapeutics, Inc. reported that Sam Martin, its Senior Vice President and Chief Financial Officer, has informed the company of his plans to retire effective on or about March 31, 2027.
Rhea-AI Filing Summary
Celldex Therapeutics, Inc. reported that Sam Martin, its Senior Vice President and Chief Financial Officer, has informed the company of his plans to retire effective on or about March 31, 2027. Martin joined Celldex in April 2009 and has served as Chief Financial Officer since July 2017.
The company has begun a search for a new Chief Financial Officer. To support continuity, Martin intends to continue serving as CFO through March 31, 2027, or until an appointed successor begins serving in that role, to help ensure a smooth transition of his responsibilities.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Retirement notice date: July 10, 2026
Planned retirement effective date: on or about March 31, 2027
Company tenure start: April 2009
+1 more
4 metrics
Retirement notice date
July 10, 2026
Date Sam Martin informed Celldex of his plans to retire as Senior Vice President and CFO
Planned retirement effective date
on or about March 31, 2027
Target effective date for Sam Martin’s retirement as CFO
Company tenure start
April 2009
Month and year Sam Martin joined Celldex Therapeutics
CFO tenure start
July 2017
Month and year Sam Martin began serving as Chief Financial Officer
Key Terms
Emerging growth company, Form 8-K, Nasdaq Capital Market, Inline XBRL
4 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Form 8-K regulatory
"20549 FORM 8-K July 10, 2026 Celldex Therapeutics"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
Nasdaq Capital Market market
"Common Stock, par value $.001 | CLDX | Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Inline XBRL technical
"104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What executive change did Celldex Therapeutics (CLDX) disclose?
Celldex Therapeutics disclosed that Sam Martin, Senior Vice President and Chief Financial Officer, plans to retire effective on or about March 31, 2027. He will remain in his role until that date or until a successor assumes the CFO position.
When will Celldex (CLDX) CFO Sam Martin’s retirement become effective?
Sam Martin’s retirement as Celldex’s CFO is expected to be effective on or about March 31, 2027. Until then, he plans to continue serving as Chief Financial Officer to support an orderly transition to his eventual successor.
How long has Celldex (CLDX) CFO Sam Martin been with the company?
Sam Martin joined Celldex in April 2009 and has served as Chief Financial Officer since July 2017. This means his planned retirement would follow a lengthy tenure at the company, including nearly a decade in the CFO role.
Is Celldex Therapeutics (CLDX) searching for a new CFO?
Celldex stated that it has initiated a search for a new Chief Financial Officer. During this process, Sam Martin intends to continue in the CFO role to help ensure a smooth handoff of responsibilities to his successor.
Will Celldex (CLDX) CFO Sam Martin remain during the transition period?
Yes. Sam Martin intends to remain as Chief Financial Officer through March 31, 2027, or until his successor begins serving. This arrangement is intended to provide continuity and support a smooth transition of his responsibilities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
